What are the precautions for using dasatinib tablets?

Dasatinib tablets are a drug used to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib mesylate.

The recommended starting dose for patients with Ph+chronic phaseCML is dasatinib100 mg, taken orally once a day. The time of administration should be consistent, either in the morning or in the evening. The recommended starting dose for patients with Ph+accelerated phase and blast phase (myeloid blast and blast phase) CML is 70mg, taken 2 times a day, taken orally in the morning and evening. Tablets must not be crushed or cut and must be swallowed whole. This product can be taken with food or on an empty stomach.

Adverse reactions that dasatinib tablets may cause include thrombocytopenia, neutropenia, anemia, pleural effusion, gastrointestinal reactions (such as diarrhea, nausea, abdominal pain and vomiting), etc. A small number of patients may experience serious adverse reactions, such as severe central nervous system bleeding or even death. During the period of medication, the patient's blood routine, liver and kidney function and other indicators should be closely monitored to detect and deal with adverse reactions in a timely manner.

Dasatinib tablets are a substrate of liver enzymes and should be avoided when combined with other drugs to avoid drug interactions. If concomitant use of drugs cannot be avoided, toxic reactions should be monitored and the dose adjusted in a timely manner. Concomitant use with erythromycin, ketoconazole, carbamazepine, dexamethasone, famotidine, omeprazole and other drugs should generally be avoided.

This product is contraindicated in patients who are allergic to dasatinib or any excipient. Pregnant and lactating women should avoid using this product or use it with caution under the guidance of a doctor. Due to lack of safety and efficacy data, use of this product is not recommended in pediatric patients. Geriatric patients do not require specific dosage adjustments, but their physical condition and response should be closely monitored.

When seeking medical treatment while taking the drug, you should inform the doctor, pharmacist and nurse that you are taking dasatinib tablets. Do not take antacids and do not consume grapefruit or grapefruit juice within two hours before or after taking this medicine. If patients experience any discomfort or suspected adverse reactions, they should consult a doctor promptly and take appropriate treatment measures.